Gevo Inc

GEVO remains entrenched in a Stage 4 decline with a clear lower-high/ lower-low sequence under declining EMAs. The recent oversold bounce stalled at the 9- and 21-EMA resistance zone, showing no sustained follow-through and leaving price extended into overhead supply. Medium-term bias is bearish; the optimal posture is to sell into strength at failed tests of these moving averages. Primary risks include a decisive breakout above the EMAs signaling a reversal or the development of a consolidation base that stabilizes price.

• ↑Insiders bought shares at ~$1.54, signaling confidence.
• ↑Q2 revenue up 7% YoY to $47M; gross profit $20M (43% margin).
• ↓Negative earnings yield and weak profitability question viability.